An editorial article has appeared in The Journal of Allergy and Clinical Immunology on the novel allergoids conjugated with mannan developed by INMUNOTEK.
“Dendritic cell targeting using C-type lectins for the improvement of allergen immunotherapy”
Stefan Schülke, PhD, Stefan Vieths, PhD
Paul-Ehrlich-Institut, Langen, Hessen, Germany
In this editorial the authors remark the immunomodulating properties of the novel allergoid-mannan glycoconjugates and their potential impact for the development of novel vaccines for allergy immunotherapy. To download the original article referred by the editorial, please click here.
Figure 1: Proposed mechanism of immune modulation by mannan-conjugated allergoids. MR: mannose receptor, DC-SIGN: dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin, Th0: naive T cell, PD-1: programmed cell death protein 1, PD-L1: programmed death-ligand 1;
J Allergy Clin Immunol. Volume 138, Issue 2, Pages 568–570 (2016). Figure with reuse permission 3984920602821